Analysts Offer Insights on Healthcare Companies: Senseonics Holdings (SENS), Dyne Therapeutics (DYN) and Agilent (A)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Senseonics Holdings (SENS – Research Report), Dyne Therapeutics (DYN – Research Report) and Agilent (A – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Senseonics Holdings (SENS)
H.C. Wainwright analyst Sean Lee CFA reiterated a Buy rating on Senseonics Holdings today and set a price target of $18.50. The company’s shares closed last Monday at $8.33.
According to TipRanks.com, CFA is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Senseonics Holdings with a $21.13 average price target.
See today’s best-performing stocks on TipRanks >>
Dyne Therapeutics (DYN)
Morgan Stanley analyst Michael Ulz maintained a Buy rating on Dyne Therapeutics yesterday and set a price target of $47.00. The company’s shares closed last Monday at $16.15, close to its 52-week low of $10.72.
According to TipRanks.com, Ulz is a 2-star analyst with an average return of
Currently, the analyst consensus on Dyne Therapeutics is a Strong Buy with an average price target of $39.43, implying a 166.8% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $50.00 price target.
Agilent (A)
In a report released yesterday, Kallum Titchmarsh from Morgan Stanley maintained a Buy rating on Agilent, with a price target of $160.00. The company’s shares closed last Monday at $118.17, close to its 52-week low of $116.36.
According to TipRanks.com, Titchmarsh is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Agilent with a $163.62 average price target, representing a 37.7% upside. In a report issued on February 26, TipRanks – PerPlexity also upgraded the stock to Buy with a $138.00 price target.
